← All stocks

Bioventus Inc.

BVS No buying or selling
CIK 0001665988 #2414 in the set updated 17 Sep 2026
Bought (1 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (1 mo)
$0.00
$0.00 on a plan · $0.00 straight out of an exercise
Sold at will
$0.00
0 of 0 sales
Net
$0.00
$0.00 against sales at will

By person

14 insiders · 0 transactions
1.4×

Robert E. Claypoole holds only 1.4 times base salary in stock. $1.19M of shares against $824.11K in salary for 2025.

Salary from the company's own proxy. The shares are what Robert E. Claypoole last reported holding, valued at $8.79, the price Class A Common Stock was last bought or sold at on the open market here, on 11 Mar 2026.

Insider
Role
Bought
Sold
Net
Holding
Worth
Change
HAWKINS WILLIAM A
Director
297,640
$2.62M
+28.6%
Singleton Mark Leonard
SVP & CFO
177,333
$1.56M
+108.9%
D'Adamio Anthony
SVP & General Counsel
153,655
$1.35M
+60.8%
NOHRA GUY P
Director
148,892
$1.31M
+48.7%
STALNECKER SUSAN M
Director
138,239
$1.21M
+74.0%
Claypoole Robert E
President and CEO
135,944
$1.19M
NEELS GUIDO J
Director
117,523
$1.03M
+100.0%
SUTTER MARTIN P
Director
117,523
$1.03M
+100.0%
Bartholdson John A.
Director
111,902
$983.24K
+145.7%
Ladone Mary Kay
Director
111,263
$977.62K
+112.0%
Beyer Pat
Director
108,718
$955.26K
+117.7%
McMurry-Heath Michelle
Director
77,279
$679.02K
+60.3%
CHURCH KATRINA J
SVP & Chief Compliance Officer
64,164
$563.78K
+55.7%
Cowdy Philip G.
Director
43,982
$386.45K
+275.9%

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.

Nothing of that kind in this period.

What was left out

Form 4 filings counted 0
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 0
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 0
History held since 16 Feb 2021